EHL BIO Co., Ltd. is a R&D institute established to discover ways for overcoming various diseases and addressing the challenges of aging. Commited to advancing research in regenerative medicine, we focus on treating conditions such as neurological, osteoarthritis, circulatory, metabolic, autoimmune diseases, anti-aging, health promotion, alopecia care, and skin care.
Through continuous enhancement of the expertise of our research personnel and innovating in stem cell application technology,
We aspire to emerge as a premier global company contributing significantly to the improvement of human health worldwide”
https://www.youtube.com/watch?v=fG-d6pH5rEw
Innovation in various stem cell application technologies
ESTHETIC
It brings beauty to customers worldwide
EHLBIO is conducting continuous research to ensure optimal health benefits through unique and specialized services focused on stem cell culture and exosome. Our commitment to continuous researc aims to deliver cutting-edge solutions to our customers.
HEALTH
We provide solutions for future medicine.
EHLBIO has successfully developed and established stable technology for stem cell extraction, separation, and culture technology. Our high stem cell extraction and excellent stem cell activity rate, have been verified through rigorous testing in our top-notch GMP facilities and technologies.
LONGEVITY
We support a life that is anticipated over one that is remembered.
EHL BIO Co., Ltd. is a R&D institute established to discover ways for overcoming various diseases and addressing the challenges of aging. Commited to advancing research in regenerative medicine. We lead the way in the development of stem cell therapy, encompassing stem cell separation, starage, cultivation, and the core of future regenerative medicine. Our efforts also extend to the commercialization of treatments and the advancement of immue cell therapy.
https://www.youtube.com/watch?v=ItbjujLRPPE
The great first step,
We are now on our way to becoming a world class entity.
EHLBIO, pioneer in Korea holds the distinction of being the first to obtain
the license for human cell disease management business, etching numerous milestones in
technology development history. Building upon this legacy, the company is evolving
into an institution that shapes a global medical culture through endeavors like
GMP compliance, clinical trials, and patent acquisition.
WORLD
CLASS
- 2012 The great first step
- February
- Establishment of EHLBIO Biological science institute
- Certified as a company-affiliated research institute by KOITA (Korea Industrial Technology Association)
- 2015 Be encouraged
- March
-Certified as a venture company by KIBO (Korea Technology Finance Corporation)
- November
- Laboratory expansion relocation
-Completed K1 GMP center (Production Capacity: 4,000) batches
- December
- Application for clinical trial: (self-fat derived stem cells / intravenous administration / atopic dermatitis)
- 2016 Prove our ability
- May
- Received Phase 1 clinical trial approval for ADSTEM® (Autologous adipose-derived stem cells, IV injection, Atopic dermatitis)
- November
- Secured start-up Growth Technology development project from the Ministry of SMEs and Start-up
- 2017 Move forward in to the world.
- July
- CPC approval by Japan's Ministry of Health, Labor and Welfare
- November
- Establishment of Representative Office in Vietnam
- December
- Completed phase 1 clinical trial of ADSTEM inj
- 2019 Lead the market
- January
- Applied phase 2 clinical trial of ADSTEM inj. (Adipose-derived stem cell)
- March
- Establishment of second GMP (per month 500LOT cultivation is possible)
- Cambodian branch (opening of a specialized hospital)
- September
- Approved phase 2 clinical trial of ADSTEM inj (World's first adipose-derived, intravenous administration)
- 2020 Bold execution
- January
- Establishment of EHLBIO Cell Center (Seoul)
- May
- CMO business for cell treatment (ATEMS)
- June
- CMO bussiness for cell treatment (PAEAN)
- 2021 From the beginning to the best
- January
- Permission for human cell and tissue management industry (No. 1)
- March
- CPC approval (First in Korea)
- May
- MOU with Dankook University Hospital Advanced Regenerative Medicine
- June
- Sign MOU on Advanced Regenerative Medicine at Chungnam National University Hospital
- 2022 Memorable 10th anniversary
- February
- Completed TCC preclinical trial
- July
- Completed Dendritic cell preclinical trial
- August
- Patient registration in phase 2 clinical trial of ADSTEM for atopic dermatits
- Applied phase 1 clinical trial for chronic renal failure (KDSC)
- September
- Headquarters relocation (Apgujeong-dong)
- 2023 To sustain business for 200 years
- Initiation of KDSC Phase 1 clinical trials
- Applied Phase 3 clinical trial for ADSC Atopic dermatitis
- IPO application
- Establishment of CPC in Indonesia / Establishment of CPC in Vietnam
- 2024 From Innovation to Standard
-
- Initiation of ADSC Phase 3 clinical trials / Appy U.S. Phase 3 clinical trial
- Enter KOSDAC
- Establishment of CPC in CIS countries
- 2025 World class bio
-
- Complete ADSC Phase 3 clinical trial and apply for NDA
EHLBIO
will protect you
We will protect you from fear with infinite thoughts and possibilities.
Adipose-derived Stem Cell Therapy
(Regenerative Medicine)
– Stem cell therapy for all diseases caused by organ or tissue hypofunction (intractable diseases such as cirrhosis, diabetes, high blood pressure, Parkinson’s disease, rheumatoid arthritis, etc.)
– Anti-aging Treatment: Anti-aging
Urine-derived stem cell therapy
(Regenerative medicine)
– It is more effective than other stem cells therapy especially for kidney, urinary, and reproductive diseases
– EHL BIO proved that UDSC is a stem cell that secretes Klotho (international thesis published / patent obtained)
– World first clinical trials for chronic kidney disease using urine-derived stem cells will be conducted
Immune cell therapy
(defense medicine)
– Combine immune cells for treatment (NK, T, DC) when bacteria or viruses have penetrated or cancer develops
Cell treatment development
– World’s first autologous stem cell treatment for atopic dermatitis (Phase 2 clinical trial is in progress)
– Treatment for autoimmune diseases (rheumatoid arthritis, etc.)
– World’s first renal failure cell treatment (by using urine-derived stem cell)
Stem cell culture media / veggie
– Developed stem cell culture media (supply raw materials to 50 domestic and foreign companies)
– Development of cell specialized stem cell culure media
– Development of Anti-cancer immune cell culture media
PROTECT
YOU
EHLBIO is
proud of our GMP facility
Quality Control Standards for Manufacturing Outstanding Drugs ( Good manufacturing practices : GMP)
Good Manufacturing Practices:GMP
Good Manufacturing and Quality Control Standards (GMP) include food, pharmaceuticals, cosmetics, and medical devices
It is the minimum standard required by licensing authorities for manufacturing and sales to maintain a consistent quality level.
GMP
600LOT cells can be
cultured per year
(500 LOT per month)
2023
3GMP establishment
All process incuding fat and blood collection, separation, cultivation, and storage are align with KGMP standards
cryogenic cell cryopreservation system
Hardware
Top-notch facilities
The highest level of GMP
Software
optimal operational
know-how
State-of-the-art clean labs
Extract only essential immune cells using Apheresis
Separate storage of S-NK, dendritic cells, and T cells
Clean Room
Biological Safety Cabinet
CO2 Incubator
Centrifuge
Inverted Microscope
Liquid Nitrogen Tank
Combining science and medicine to create world-class medicines
CLINICAL
TRIALS
It’s EHLBIO, sustaining business for
200 years to contribute to human health
Based on its extensive history and expertise in the field of stem and immune cells,
EHL BIO is producing meaningful research outcomes through continuous efforts in
diseases and health research.
In addition, we are focusing on developing innovative treatments by establishing the
top-notch GMP facilities and fostering collaborations with domestic and foreign
hospitals and research institutes.
EHLBIO is currently on a stunning journey toward a 200 year enterprise,
aiming to contribute to human health.
